StockData
Phathom Pharmaceuticals, Inc. logo

Phathom Pharmaceuticals, Inc. (PHAT) stock

PHATNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 4/30
$5.50−0.38 (-6.46%)

Close on Nov 17, 2026Market cap $447.10MP/E –Yield –

Phathom Pharmaceuticals operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

Phathom Pharmaceuticals's operating income for the twelve months ending Sep 30, 2026 was -$25.46M. For fiscal 2025 it was -$159.99M. The highest annual figure on record is -$1.23M in fiscal 2018.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$159.99M–
FY2024Dec 31, 2024-$277.47M–
FY2023Dec 31, 2023-$167.31M–
FY2022Dec 31, 2022-$172.44M–
FY2021Dec 31, 2021-$135.08M–
FY2020Dec 31, 2020-$125.67M–
FY2019Dec 31, 2019-$106.22M–
FY2018Dec 31, 2018-$1.23M–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026-$85.00K–
Q2 FY2026Jun 30, 2026-$3.97M–
Q1 FY2026Mar 31, 2026-$15.48M–
Q4 FY2025Dec 31, 2025-$5.93M–
Q3 FY2025Sep 30, 2025-$15.27M–
Q2 FY2025Jun 30, 2025-$59.92M–
Q1 FY2025Mar 31, 2025-$78.86M–
Q4 FY2024Dec 31, 2024-$59.42M–
Q3 FY2024Sep 30, 2024-$70.80M–
Q2 FY2024Jun 30, 2024-$77.30M–
Q1 FY2024Mar 31, 2024-$69.95M–
Q4 FY2023Dec 31, 2023-$69.88M–
Q3 FY2023Sep 30, 2023-$35.66M–
Q2 FY2023Jun 30, 2023-$31.70M–
Q1 FY2023Mar 31, 2023-$30.08M–
Q4 FY2022Dec 31, 2022-$46.64M–
Q3 FY2022Sep 30, 2022-$42.53M–
Q2 FY2022Jun 30, 2022-$45.36M–
Q1 FY2022Mar 31, 2022-$37.91M–
Q4 FY2021Dec 31, 2021-$33.04M–
Q3 FY2021Sep 30, 2021-$33.14M–
Q2 FY2021Jun 30, 2021-$35.32M–
Q1 FY2021Mar 31, 2021-$33.58M–
Q4 FY2020Dec 31, 2020-$52.44M–
Q3 FY2020Sep 30, 2020-$32.83M–
Q2 FY2020Jun 30, 2020-$20.02M–
Q1 FY2020Mar 31, 2020-$20.38M–
Q4 FY2019Dec 31, 2019-$15.69M–
Q3 FY2019Sep 30, 2019-$6.28M–
Q2 FY2019Jun 30, 2019-$83.01M–
Q1 FY2019Mar 31, 2019-$1.23M–
Q4 FY2018Dec 31, 2018-$451.00K–
Q3 FY2018Sep 30, 2018-$268.00K–
Q2 FY2018Jun 30, 2018-$255.00K–
Q1 FY2018Mar 31, 2018-$251.00K–

More Phathom Pharmaceuticals figures

See a number that looks wrong?